Cited by 27Alzheimer's disease research and treatmentsNanoplatforms for cancer theranosticsNanoparticle-Based Drug Delivery

Tau‑targeting multifunctional nanocomposite based on tannic acid-metal for near-infrared fluorescence/magnetic resonance bimodal imaging-guided combinational therapy in Alzheimer's disease

Open access
Gu, Yutian, Zhang, Qin, Huang, Honglin, Ho, Kwun Hei Willis, Zhang, Yu, Yi, Changqing, Zheng, Yifan, Chang, Raymond Chuen Chung +2 more·2024·Theranostics

Abstract

Rationale: Alzheimer's disease (AD) is hallmarked by amyloid-β (Aβ) plaques and hyperphosphorylated tau (p-tau) neurofibrillary tangles.While Aβ-centric therapies have shown promise, the complex pathology of AD requires a multifaceted therapeutic approach.The weak association between Aβ levels and cognitive decline highlights the need for alternative theranostic strategies.Currently, oxidative stress and tau hyperphosphorylation are now recognized as critical pathological events in AD.Thus, therapies that concurrently attenuate oxidative stress damage and inhibit tau pathology hold great potential for AD treatment.Methods: Herein, a multifunctional neuron-targeted nanocomposite is devised to realize dual imaging-guided AD therapy, integrating the inhibition of tau pathology and reactive oxygen species (ROS)-neutralizing biofunctions.The construction of the nanocomposite incorporates polyphenolic antioxidants tannic acid (TA)-based nanoparticles carrying manganese ions (Mn 2+ ) and fluorescent dye IR780 iodide (IR780), coupled with a neuron-specific TPL peptide.The resulting IR780-Mn@TA-TPL nanoparticles (NPs) are comprehensively evaluated in both in vitro and in vivo AD models to assess their imaging capabilities and therapeutic efficacy.Results: The nanocomposite facilitates Mn-enhanced magnetic resonance (MR) imaging and near-infrared (NIR) fluorescence imaging.It effectively neutralizes toxic ROS and reduces tau hyperphosphorylation and aggregation.In AD rat models, the nanocomposite restores neuronal density in the hippocampus and significantly improves spatial memory.Conclusions: Such a neuron-targeting multifunctional nanocomposite represents a potential theranostic strategy for AD, signifying a shift towards bimodal imaging-guided treatment approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7150/thno.98462

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tau protein serves as a target far less frequently, where systems combine hyperphosphorylated tau targeting with therapies reducing oxidative stress and inhibiting Aβ aggregation.

    “Tau protein serves as a target far less frequently, where systems combine hyperphosphorylated tau targeting with therapies reducing oxidative stress and inhibiting Aβ aggregation [64,72].”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [72]

    The Conclusions (page unavailable) report that the nanocomposite mitigates oxidative stress and tau hyperphosphorylation, and inhibits subsequent tau aggregation. The Introduction describes substantial prior emphasis on Aβ-centric interventions, but the paper does not establish how much less frequently tau is targeted. It does not report inhibition of Aβ aggregation by this system; the reported aggregation effect concerns tau. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • In animal models, reduction in amyloid plaque burden, decrease in neuroinflammation and oxidative stress, and improvement in cognitive functions in behavioral tests have been demonstrated.

    “In animal models, a reduction in the burden of amyloid plaques [58,68,75], a decrease in neuroinflammation and oxidative stress, as well as an improvement in cognitive functions in behavioral tests [58,64,72,73,83,85] have been demonstrated.”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [72]

    The Results and Discussion section on in vivo therapeutic outcomes reports improved Y-maze performance and reduced cerebral ROS in treated AD-model rats, supporting the cognitive and oxidative-stress parts of the claim. Our copy does not report a decrease in neuroinflammation or amyloid plaque burden; it measures tau pathology rather than plaque burden. No page number is available in the indexed passages. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Alternative targeting strategies include peptide ligands targeting hyperphosphorylated tau, BBB penetration property, small molecules binding beta-sheet structure, and electrostatic interactions.

    “Alternative strategies include the use of peptide ligands targeting hyperphosphorylated tau protein [64] or the property of penetrating the BBB [58,72], as well as small molecules that bind to the beta-sheet structure of amyloid fibrils [83]. In some works, specificity is achieved through electrostatic interactions between the charged surface of Nps and negatively charged amyloid aggregates [68].”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [72]

    The Results and Discussion sections report that TPL-peptide-modified nanoparticles bind tau aggregates and cross an in vitro BBB model. But the paper describes TPL as a neuron-targeting peptide; it does not show that the peptide ligand itself specifically targets hyperphosphorylated tau. The claims about amyloid-binding small molecules and electrostatic interactions are attached to other citations in the citing sentence. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • The effectiveness of therapy is confirmed in most studies on cellular models, where a significant increase in survival of neuronal cells upon exposure to toxic concentrations of Aβ is shown.

    “The effectiveness of therapy is confirmed in most studies on cellular models, where a significant increase in the survival of neuronal cells upon exposure to toxic concentrations of Aβ is shown [29,64,72,76,77,78,80,83].”

    From Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions (2026) · cites this paper as [72]

    The Results and Discussion section, under “Mitigation of intracellular oxidative stress” (page unavailable), reports increased PC12 cell viability after nanocomposite treatment. However, the cells were injured with okadaic acid, not exposed to toxic concentrations of Aβ. This source therefore supports improved survival in a cellular model, but not the claimed Aβ-exposure condition. (LLM, conf=0.90)

    Experimental — accuracy not yet measured
  • A number of studies employ multimodal approaches, combining MRI with PET, SPECT, or fluorescence imaging, which compensates for the limitations of each method individually.

    “A number of studies employ multimodal approaches, combining MRI with PET [64], SPECT [70,71], or fluorescence imaging [72,75], which compensates for the limitations of each method individually.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [34]Xu S Yang P Qian K Li Y Guo Q Wang P Modulating autophagic flux via ROS-responsive targeted micelles to restore neuronal proteostasis in Alzheimer's disease Bioact Mater 2022 11 300 316 34977433 PMC8668445

Cited by

Sorted by citations

Authors
Gu, Y., Zhang, Q., Huang, H., Ho, K. H. W., Zhang, Y., Yi, C., Zheng, Y., Chang, R. C. C., Wang, E. S., & Yang, M.
Affiliations
  • Hong Kong Polytechnic University (HK)
  • Sun Yat-sen University (CN)
  • University of Hong Kong (HK)
Corresponding author
  • Zhang, Qin
  • Yang, Mo
Venue
Theranostics
Published
2024
Volume
14
Issue
16
Pages
6218-6235
ISSN
1838-7640 (ISSN-L)
OpenAlex
W4403545526
Cited by
27
References
52
Citations by year
2026: 17 · 2025: 10
FWCI
7.68
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Theranostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PolyU Institutional Research Archive (Hong Kong Polytechnic University) (publishedVersion, cc-by)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
Keywords
Alzheimer's disease, tau hyperphosphorylation, manganese-enhanced MRI, near-infrared fluorescence imaging, dual-modality imaging, reactive oxygen species scavenging, oxidative stress, IR780, tau aggregation, spatial memory, hippocampus
MeSH terms
Theranostic Nanomedicine, Alzheimer Disease, Animals, Combined Modality Therapy, Disease Models, Animal, Humans, Magnetic Resonance Imaging, Manganese, Neurons, Tannins, tau Proteins, Reactive Oxygen Species, Oxidative Stress, Rats, Nanocomposites, Polyphenols, Optical Imaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review